L3VLUP
ProSign in

PFE · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

PFEVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • PFE
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterPFEVRTX
Q3 202027 holders, $24.9bn31 holders, $21.9bn
Q4 202024 holders, $24.4bn30 holders, $18.4bn
Q1 202128 holders, $22.8bn31 holders, $15.4bn
Q2 202125 holders, $25.0bn30 holders, $12.7bn
Q3 202135 holders, $27.3bn35 holders, $10.1bn
Q4 202134 holders, $38.6bn28 holders, $12.4bn
Q1 202234 holders, $33.0bn23 holders, $16.1bn
Q2 202226 holders, $33.9bn25 holders, $18.1bn
Q3 202235 holders, $28.7bn22 holders, $18.4bn
Q4 202232 holders, $32.8bn28 holders, $18.4bn
Q1 202335 holders, $27.0bn26 holders, $21.4bn
Q2 202331 holders, $23.0bn27 holders, $24.7bn
Q3 202337 holders, $22.0bn33 holders, $24.3bn
Q4 202333 holders, $18.8bn32 holders, $28.6bn
Q1 202429 holders, $15.2bn31 holders, $29.8bn
Q2 202432 holders, $14.6bn29 holders, $33.4bn
Q3 202429 holders, $13.2bn27 holders, $33.5bn
Q4 202434 holders, $11.4bn26 holders, $28.5bn
Q1 202534 holders, $9.3bn21 holders, $35.4bn
Q2 202528 holders, $7.8bn21 holders, $32.3bn
Q3 202529 holders, $7.4bn22 holders, $25.9bn
Q4 202526 holders, $6.4bn26 holders, $31.8bn
Q1 202624 holders, $7.9bn25 holders, $31.8bn
Q2 202622 holders, $5.2bn26 holders, $34.6bn
PFE

Pfizer Inc

Holders
29
Reported value
$7.4bn
Buyers
19
Sellers
12

Breadth +7 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
VRTX

Vertex Pharmaceuticals Inc

Holders
22
Reported value
$25.9bn
Buyers
13
Sellers
10

Breadth +3 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q3 2025

Among the 39 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only PFE (17)

Acadian Asset Management LLC, AQR Capital Management LLC, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Caxton Associates LLP, Citadel Advisors LLC, D. E. Shaw & Co., Dodge & Cox, Eisler Capital Management Ltd, ExodusPoint Capital Management LP, GAMCO Investors Inc, Jane Street Group LLC, Marshall Wace LLP, Schonfeld Strategic Advisors LLC, Susquehanna International Group LLP, Walleye Capital LLC, Winton Group Ltd

Only VRTX (10)

ARK Investment Management LLC, Baillie Gifford & Co, Bridgewater Associates LP, Capital Research Global Investors, Fidelity (FMR LLC), Freestone Grove Partners LP, Hudson Bay Capital Management LP, Janus Henderson Group Ltd, Tudor Investment Corp, Voloridge Investment Management LLC

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →